{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:34:26Z","timestamp":1745469266334,"version":"3.40.4"},"reference-count":32,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T00:00:00Z","timestamp":1389916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Safety and efficacy of paricalcitol in hemodialysis patients with secondary hyperparathyroidism (sHPT) was investigated under routine clinical practice in German and Austrian dialysis centers. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Hemodialysis patients with sHPT initiating intravenous paricalcitol were enrolled in this noninterventional study regardless of concomitant sHPT treatment. Prior active vitamin D therapy was discontinued. Clinical laboratory values, including intact parathyroid hormone (iPTH), total serum calcium (Ca), phosphorus (P), Ca \u00d7 P product, and alkaline phosphatase (AP), were recorded for 6 months following initiation of paricalcitol treatment. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; 1,313 patients (Austria, n = 280; Germany, n = 1,033) from 169 dialysis centers were enrolled. Most patients (n = 932; 79.1%) had received dialysis for \u22651 year. Median iPTH fell from 518.9 pg\/ml [55.0 pmol\/l] at baseline to 264.0 pg\/ml [28.0 pmol\/l] after 6 months (p &lt; 0.0001). After 6 months of treatment, \u226530 and \u226560% reductions in iPTH were observed in 63.0 and 35.9% of patients, respectively. At 6 months, 27.2% of patients achieved iPTH levels between 150 and &lt;300 pg\/ml [15.9 and &lt;31.8 pmol\/l] compared with 9.7% at baseline. Ca, P, and Ca \u00d7 P levels remained stable in the majority of patients. AP levels declined from a median of 98 U\/l at baseline to 83 U\/l (p &lt; 0.0001) at 6 months. Monitoring of adverse events and clinical laboratory assessments identified no unexpected safety signals for paricalcitol. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; Paricalcitol is an effective and well-tolerated treatment option for the control of iPTH levels in hemodialysis patients with sHPT. The results of this study support the results of previous trials under real-time clinical practice conditions in Austria and Germany.<\/jats:p>","DOI":"10.1159\/000357677","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T08:25:10Z","timestamp":1389947110000},"page":"39-50","source":"Crossref","is-referenced-by-count":2,"title":["Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A German-Austrian, Single-Arm, Open-Label, Prospective, Noninterventional, Observational Study"],"prefix":"10.1159","volume":"126","author":[{"given":"Patrick","family":"Biggar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Klauser-Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Walter","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andras","family":"Veres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Seidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1210%2Fjcem-67-5-876"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1093%2Fndt%2F15.suppl_5.18"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1053%2Fajkd.2002.36899"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1046%2Fj.1523-1755.2003.00878.x"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1359%2Fjbmr.070305"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1093%2Fndt%2Fgfr555"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1056%2FNEJMoa022536"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1001%2Fjama.2012.120"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1016%2Fj.ahj.2012.09.018"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1159%2F000109398"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1016%2FS0272-6386%2803%2900111-2"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.1681%2FASN.2007040449"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1007%2Fs11560-011-0538-2"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.1093%2Fndt%2Fgfs018"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.1093%2Fndt%2Fgfr531"},{"doi-asserted-by":"publisher","key":"ref16","DOI":"10.2215%2FCJN.01040308"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.1046%2Fj.1523-1755.2002.00434.x"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1067%2Fmlc.2002.122819"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.1038%2Fsj.ki.5001514"},{"doi-asserted-by":"publisher","key":"ref20","DOI":"10.1159%2F000266204"},{"doi-asserted-by":"publisher","key":"ref21","DOI":"10.1038%2Fki.2011.226"},{"doi-asserted-by":"publisher","key":"ref22","DOI":"10.1093%2Fndt%2Fgfq219"},{"doi-asserted-by":"publisher","key":"ref23","DOI":"10.1038%2Fsj.ki.5002406"},{"doi-asserted-by":"publisher","key":"ref24","DOI":"10.1053%2Fajkd.1998.v32.pm9820470"},{"doi-asserted-by":"publisher","key":"ref25","DOI":"10.1681%2FASN.2008010014"},{"doi-asserted-by":"publisher","key":"ref26","DOI":"10.2215%2FCJN.06091108"},{"doi-asserted-by":"publisher","key":"ref27","DOI":"10.1093%2Fndt%2Fgfp144"},{"doi-asserted-by":"publisher","key":"ref28","DOI":"10.2215%2FCJN.03591006"},{"doi-asserted-by":"publisher","key":"ref29","DOI":"10.2215%2FCJN.03790808"},{"doi-asserted-by":"publisher","key":"ref30","DOI":"10.1053%2Fajkd.2001.28114"},{"doi-asserted-by":"publisher","key":"ref31","DOI":"10.1111%2Fj.1440-1797.2010.01398.x"},{"doi-asserted-by":"publisher","key":"ref32","DOI":"10.1159%2F000169179"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/357677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/357677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:30:29Z","timestamp":1745433029000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000357677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,4,1]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000357677","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"type":"electronic","value":"1660-2110"}],"subject":[],"published":{"date-parts":[[2014,1,17]]}}}